Akari Therapeutics PLC 8-K filings

Akari Therapeutics Plc held its Annual General Meeting on June 30, 2026, where shareholders voted on various resolutions, including the re-election of directors and auditor ratification.

Akari Therapeutics has amended its securities purchase agreement to consolidate the second and third tranches of its private placement into a single closing on June 26, 2026.

Akari Therapeutics has entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a private placement of units.

Akari Therapeutics will implement a 1-for-40 reverse split of its American Depositary Shares to meet Nasdaq's minimum bid price requirement.

Akari Therapeutics shareholders approved the exercisability of warrants covering over 44 million American Depositary Shares, enabling the issuance of underlying ordinary shares.

Akari Therapeutics announced a $9 million financing package, combining a $5 million equity raise with a $4 million debt-to-equity conversion, to fund R&D and improve its capital structure.

Akari Therapeutics shareholders approved all six resolutions at a Special General Meeting, including warrant exercisability, share subdivision, new share allotment authority, and adoption of new articles of association.

Akari Therapeutics, Plc has furnished an investor presentation for upcoming conferences and meetings.

Akari Therapeutics received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Akari Therapeutics, Plc announced the appointment of Kameel Farag as its interim Chief Financial Officer, effective October 22, 2025, succeeding Torsten Hombeck.

Akari Therapeutics raises $2.5 million through a registered direct offering of ADSs and a concurrent private placement of Series E and F warrants to fund R&D.

Akari Therapeutics announced a $2.5 million registered direct offering and concurrent private placement to fund working capital and R&D.

Akari Therapeutics, PLC announced the closing of its August 2025 Notes Offering, raising $3 million through the issuance of unsecured promissory notes.

Akari Therapeutics announced an extension of convertible notes and warrants, along with promising preclinical data for its novel ADC payload PH1 in prostate cancer, while also closing a tranche of its August 2025 notes offering.

Akari Therapeutics, Plc entered into a $25 million equity line of credit agreement with White Lion Capital, LLC and announced the resignation of its Chief Financial Officer, Torsten Hombeck.

Akari Therapeutics completed the first tranche of its unsecured promissory notes offering, raising $2.26 million and extending warrants for certain investors, including its Chairman.

Akari Therapeutics, Plc announced the availability of an updated investor presentation for use in various meetings.

Akari Therapeutics, Plc shareholders approved all resolutions at the Annual General Meeting on June 30, 2025, including a substantial increase in the equity incentive plan share pool and new stock option awards for directors, alongside re-electing the board and authorizing future share allotments.

Akari Therapeutics announced its Q1 2025 financial results, highlighting a reduced net loss and progress in its ADC development program.

Akari Therapeutics announced its full year 2024 financial results, highlighting progress in its ADC pipeline and a corporate update including a new CEO appointment.

Akari Therapeutics, Plc appoints Abizer Gaslightwala as its new President and Chief Executive Officer, effective on or around April 21, 2025, replacing Dr. Samir R. Patel, who will remain on the Board.

Akari Therapeutics secures $7.1 million through a private placement of unregistered American Depository Shares (ADS) and warrants, with significant participation from its Chairman and board members.

Akari Therapeutics is advancing a novel bi-functional antibody drug conjugate (ADC) platform with a unique spliceosome inhibitor payload, aiming to overcome limitations of current cancer therapies.

Akari Therapeutics has appointed Samir R. Patel as Chief Executive Officer and Abizer Gaslightwala as a new director, while Michael Grissinger has resigned from the board, all effective December 16, 2024.

Akari Therapeutics has appointed Torsten Hombeck as its new Chief Financial Officer, effective December 16, 2024.

Akari Therapeutics has announced the departure of its Interim Chief Financial Officer, Wendy DiCicco, and the appointment of Samir Patel as Interim Principal Financial Officer and Principal Accounting Officer.

Akari Therapeutics has finalized its merger with Peak Bio, raised $3.2 million through a private placement, and secured a $50 million equity line of credit.

Akari Therapeutics shareholders have approved the merger with Peak Bio, Inc., paving the way for the creation of a combined entity focused on antibody-drug conjugates and geographic atrophy therapies.

Akari Therapeutics has received a delisting notice from Nasdaq after failing to meet minimum stockholders' equity requirements, but intends to appeal the decision.

Akari Therapeutics has expanded its board of directors with the appointment of Robert Bazemore and amended the compensation structure for its Interim CEO, Samir R. Patel, while also providing updates on its pending merger with Peak Bio.